Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 4/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054826 | 0.81 | PRKDC (0.72) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL25062364 | 0.81 | GSK3B (0.51) | MAPTPKMALDH1A1KDM4EHTT | |
| SCHEMBL7568311 | 0.80 | PRKDC (0.62) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29776854 | 0.79 | PRKDC (1.00) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL600210 | 0.79 | PRKDC (1.00) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3927915 | 0.78 | KMO (0.62) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5058586 | 0.78 | PRKDC (0.67) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL21160054 | 0.78 | PRKDC (0.67) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5058525 | 0.78 | PRKDC (0.75) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4992024 | 0.76 | PRKDC (0.73) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104557871-B | Arylmorpholine compounds with spiro substituents as well as preparation method and use thereof | 上海汇伦生命科技有限公司 | 2017-05-03 | — | — | CN | claimed |
| CN-104557871-A | Arylmorpholine compounds with spiro substituents as well as preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD | 2015-04-29 | — | — | CN | claimed |
| CN-102670617-B | Application of ibuprofen 2-(2-arylmorpholine-4-yl) ethyl ester in preparation of antidepressant drugs | UNIV HUNAN | 2013-03-20 | — | — | CN | claimed |
| CN-102532061-A | Method for easily preparing aryl morpholine and aryl piperidine | UNIV EAST CHINA SCIENCE & TECH | 2012-07-04 | — | — | CN | claimed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| CN-1402720-A | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER PROD INC (US) | 2003-03-12 | — | — | CN | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| CN-111153891-B | Substituted benzimidazole PI3K alpha/mTOR double-target inhibitor and pharmaceutical composition and application thereof | 贵州医科大学 | 2023-03-31 | — | — | CN | disclosed |
| CN-111153891-A | Substituted benzimidazole PI3K α/mTOR double-target inhibitor and pharmaceutical composition and application thereof | 贵州医科大学 | 2020-05-15 | — | — | CN | disclosed |
| CN-108191837-A | PI3K α/mTOR bidifly enzyme inhibitors and its pharmaceutical composition and application | 贵州医科大学 | 2018-06-22 | — | — | CN | disclosed |
| CN-107001522-A | Polymerization catalyst composition and method of using the same | 株式会社普利司通 | 2017-08-01 | — | — | CN | disclosed |
| CN-104557955-B | Tricyclic compound as PI3K/mTOR inhibitor as well as preparation method and application of tricyclic compound | 上海汇伦生命科技有限公司 | 2017-05-03 | — | — | CN | disclosed |
| CN-104557871-B | Arylmorpholine compounds with spiro substituents as well as preparation method and use thereof | 上海汇伦生命科技有限公司 | 2017-05-03 | — | — | CN | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| CN-1738808-A | Cyclization process for substituted benzothiazole derivatives | HOFFMANN LA ROCHE (CH) | 2006-02-22 | — | — | CN | disclosed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| CN-1402720-A | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER PROD INC (US) | 2003-03-12 | — | — | CN | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | PRKDC 17/4885PIK3CD 829/4885PIK3CA 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.